Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug and defibrillator interactions

C A Carnes1, A A Mehdirad, S D Nelson

  • 1College of Pharmacy, The Ohio State University, Columbus 43210, USA.

Pharmacotherapy
|June 10, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

Sorption/Desorption of lincomycin from three arid-region soils.

Journal of environmental quality·2013
Same author

Comparison of equilibrium and non-equilibrium distribution coefficients for the human drug carbamazepine in soil.

Chemosphere·2013
Same author

Myocardial expression of hyperpolarization-activated, cyclic nucleotide-gated proteins in healthy cats and cats with hypertrophic cardiomyopathy.

Schweizer Archiv fur Tierheilkunde·2013
Same author

Pharmacokinetics of oral ivabradine in healthy cats.

Journal of veterinary pharmacology and therapeutics·2010
Same author

Efficacy and uptake of soil-applied imidacloprid in the control of Asian citrus psyllid and a citrus leafminer, two foliar-feeding citrus pests.

Journal of economic entomology·2010
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Drug interactions with implantable cardioverter defibrillators (ICDs) can be beneficial or harmful. Pharmacists must understand these drug-device interactions to optimize patient care and device function.

Area of Science:

  • Cardiology
  • Clinical Pharmacy
  • Biomedical Engineering

Background:

  • Implantable cardioverter defibrillators (ICDs) are crucial for managing life-threatening arrhythmias.
  • The increasing prevalence of ICDs necessitates a comprehensive understanding of factors influencing their efficacy and safety.
  • Drug-device interactions represent a significant, yet often overlooked, aspect of patient management.

Purpose of the Study:

  • To review and synthesize existing literature on the interactions between pharmacological agents and defibrillators, particularly ICDs.
  • To delineate the potential beneficial and detrimental effects of these drug-device interactions.
  • To raise awareness among healthcare professionals, especially pharmacists, regarding these interactions.

Main Methods:

Related Experiment Videos

  • A systematic literature search was conducted using MEDLINE from 1966 to the present.
  • Reference lists of identified articles were also reviewed to identify additional relevant sources.
  • The review focused on studies detailing drug effects on defibrillator function and patient outcomes.

    • Main Results:

    • Drugs can beneficially reduce defibrillation energy requirements, decrease arrhythmia occurrence, lower shock frequency, prolong device longevity, and improve patient comfort.
    • Harmful interactions may alter ventricular tachycardia detection, affect pacing thresholds (interfering with bradycardia or antitachycardia pacing), induce incessant ventricular tachycardia, or increase defibrillation energy needs.
    • The impact of drug-device interactions varies, highlighting the complexity of managing patients with ICDs.

    Conclusions:

    • Pharmacological agents possess the potential for both positive and negative interactions with defibrillator therapy.
    • Awareness of these drug-device interactions is critical for pharmacists to ensure optimal patient outcomes and device performance.
    • Proactive management and communication regarding drug-device interactions are essential as ICD use continues to expand.